Panel Discussion: How Early Clinical Learnings Can Inform Smarter Preclinical Strategy for Antifibrotic Drug Development
Time: 10:00 am
day: Conference Day Two
Details:
As more antifibrotics enter early-phase clinical trials, translating bedside learnings back into the lab has never been more important. This panel gathers experts in early clinical development to examine how clinical signals, can be mined to refine target selection, guide biomarker validation, and improve preclinical model design.
- How Phase 2 outcomes including responder subtypes are informing updates to preclinical models for improved translational relevance to refine preclinical models with clinical feedback
- Uncover strategies across disease areas to incorporate biomarkers, imaging, and functional readouts into preclinical studies that mirror clinical endpoints and support future regulatory alignment to embed clinically meaningful endpoints earlier
- Exploring how best to apply Phase 2 learnings to strengthen preclinical data packages, optimizing dosing, toxicology thresholds, and study design to de-risk early development for smarter IND enabling packages
- Using insights from heterogenous patient responses to refine hypotheses, select more predictive models, and prioritize mechanisms likely to succeed in defined populations
